FMP
PTC Therapeutics, Inc.
PTCT
NASDAQ
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
54.5 USD
1.74 (3.19%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
159.74M
305.44M
437.86M
582.02M
714.73M
1.05B
1.56B
2.3B
3.39B
5B
-
91.21
43.35
32.93
22.8
47.57
47.57
47.57
47.57
1.51M
106.37M
143.57M
221.51M
233.41M
293.81M
433.57M
639.83M
944.22M
1.39B
0.95
34.82
32.79
38.06
32.66
27.86
27.86
27.86
27.86
-8.72M
87.53M
120.19M
197.15M
209.3M
240.06M
354.27M
522.8M
771.5M
1.14B
-5.46
28.66
27.45
33.87
29.28
22.76
22.76
22.76
22.76
10.24M
18.84M
23.39M
24.36M
24.11M
53.74M
79.31M
117.04M
172.71M
254.88M
6.41
6.17
5.34
4.19
3.37
5.1
5.1
5.1
5.1
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)